Sec. 8. (a) For substitution to occur for a prescription other than a prescription filled under the Medicaid program (42 U.S.C. 1396 et seq.), the children's health insurance program established under IC 12-17.6-2, the biosimilar biological products requirements under IC 16-42-25, or the Medicare program (42 U.S.C. 1395 et seq.): (1) the practitioner must: (A) sign on the line under which the words "May substitute" appear; or (B) for an electronically transmitted prescription, electronically transmit the instruction "May substitute."; and (2) the pharmacist must inform the customer of the substitution. (b) This section does not authorize any substitution other than substitution of a generically equivalent drug product. [Pre-1993 Recodification Citation: 16-6-8.1-2(c).] As added by P.L.2-1993, SEC.25. Amended by P.L.239-1999, SEC.7; P.L.291-2001, SEC.233; P.L.204-2005, SEC.10; P.L.96-2014, SEC.5.
IC 16-42-22-9 Transmission of practitioner's instructions to pharmacist Sec. 9. If the practitioner communicates instructions to the pharmacist orally or electronically, the pharmacist shall: (1) indicate the instructions in the pharmacist's own handwriting on the written copy of the prescription order; or (2) record the electronically transmitted instructions in an electronic format. [Pre-1993 Recodification Citation: 16-6-8.1-2(d).] As added by P.L.2-1993, SEC.25. Amended by P.L.204-2005, SEC.11.